News & Updates

One in six CYPs in SG develop long COVID
One in six CYPs in SG develop long COVID
11 Dec 2023
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023 byAudrey Abella

In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.

Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023